Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLC
The FDA has approved AstraZeneca’s Imfinzi to treat limited-stage small cell lung cancer, adding another lung cancer indication to one of the pharma’s best-selling drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
